TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16360972

Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (18 microg CIFN for 8 weeks, then 9 microg for 40 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: CIFN plus ribavirin (9 microg CIFN for 48 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (both interventions)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (induction-dosing)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (sustained responders and relapse patients)
Number of subjects: 77
Study: 15296484

Group type: EXPERIMENTAL
Intervention: Term pregnancy milk (Interval A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preterm pregnancy milk (Interval A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Term pregnancy serum (Interval A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preterm pregnancy serum (Interval A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Term pregnancy milk (Interval B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preterm pregnancy milk (Interval B)
Number of subjects: 33
Study: 11095445

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 microg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study: 9494772

Group type: EXPERIMENTAL
Intervention: 5 mg norethisterone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg norethisterone acetate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg norethisterone acetate
Number of subjects: 24
Study: 7692687

Group type: EXPERIMENTAL
Intervention: 3-week therapy series of ultrasound (6 times a week)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 6-week therapy series of ultrasound (3 times a week)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9-week therapy series of ultrasound (2 times a week)
Number of subjects: 150
Study: 3533025

Group type: EXPERIMENTAL
Intervention: Heated nebulization of Salbutamol at 37 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nebulization of Salbutamol
Number of subjects: 40
Study: 28045553

Group type: EXPERIMENTAL
Intervention: Segmental training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control)
Number of subjects: 28
Study: 26823602

Group type: EXPERIMENTAL
Intervention: First-line bevacizumab-based therapy
Number of subjects: 181
Study: 22496207

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (4 days treatment, n = 5)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (no treatment, n = 5)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (long-term treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (long-term treatment)
Number of subjects: 53
Study: 20551726

Group type: EXPERIMENTAL
Intervention: Interactive web‐based training (COPE: Collaborative Opioid Prescribing Education)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Both groups (web training and control)
Number of subjects: 213
Study: 19085342

Group type: COMPARATOR
Intervention: Candesartan 32 mg
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Candesartan-HCT 32/12.5 mg
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Candesartan-HCT 32/25 mg
Number of subjects: 1975
Study: 15844675

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Self-help information package (Control)
Number of subjects: 165
Study: 11919438

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study: 10357049

Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 238
Study: 8733702

Group type: EXPERIMENTAL
Intervention: Oral misoprostol for mucositis prophylaxis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for mucositis prophylaxis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1656517

Group type: EXPERIMENTAL
Intervention: 2.0 g/day omega-3-PUFA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4.0 g/day omega-3-PUFA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7044407

Group type: EXPERIMENTAL
Intervention: CTG report available to clinician
Number of subjects: 300

Group type: COMPARATOR
Intervention: CTG report withheld from clinician
Number of subjects: 300
Study: 31490536

Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulphate plus aspirin (600 mg on day 1, then 75 mg per day through day 90; plus 50 to 325 mg of aspirin per day)
Number of subjects: 4881

Group type: COMPARATOR
Intervention: Placebo plus aspirin (same range of dosages as clopidogrel)
Number of subjects: 4881

Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulphate plus aspirin
Number of subjects: 4881

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 4881
Study: 25311333

Group type: EXPERIMENTAL
Intervention: Single-arm trial intervention including a one-time, half-day educational session with targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling.
Number of subjects: 37
Study: 23843526

Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis applied to fMRI data
Number of subjects: 0
Study: 21696078

Group type: EXPERIMENTAL
Intervention: Fistulotomy with marsupialization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 50
Study: 20178283

Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 25%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 50%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 75%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 100%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Task complexity (simple and complex)
Number of subjects: 120
Study: 15969777

Group type: COMPARATOR
Intervention: didanosine (ddI)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: didanosine (ddI) + stavudine (d4T)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: stavudine (d4T)
Number of subjects: 116
Study: 12462350

Group type: EXPERIMENTAL
Intervention: Porcine secretin infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic human secretin infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 0
Study: 10325257

Group type: EXPERIMENTAL
Intervention: Gonadotrophin stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transvesical ultrasound
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Surgical neovagina construction
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vaginal dilators
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hormonal response to gonadotrophin stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pregnancy outcome
Number of subjects: 12
Study: 9199740

Group type: EXPERIMENTAL
Intervention: MK-507
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol (as add-on therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Timolol and Betaxolol (as control)
Number of subjects: 20
Study: 1756844

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1.6 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6961762

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg i.v. over 5 min
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg orally
Number of subjects: 5
Study: 30523432

Group type: EXPERIMENTAL
Intervention: Nutritional education intervention focusing on gut microbiota composition
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 29145894

Group type: EXPERIMENTAL
Intervention: 2 g of myo‐inositol twice daily for 12 months
Number of subjects: 164

Group type: COMPARATOR
Intervention: Identical placebo twice daily for 12 months
Number of subjects: 164
Study: 25537234

Group type: EXPERIMENTAL
Intervention: Educational intervention (group sessions and educational material)
Number of subjects: 7498
Study: 24276074

Group type: EXPERIMENTAL
Intervention: AboBTXA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 23084759

Group type: COMPARATOR
Intervention: Control (C) treatment with 150g/d of diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate restriction (M) with 105g/d of diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Severe restriction (S) with 75g/d of diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Refed moderate restriction (MF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Refed severe restriction (SF)
Number of subjects: 40
Study: 20027431

Group type: COMPARATOR
Intervention: Dry heat sterilization (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Autoclave sterilization (G2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microwave irradiation (G3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde sterilization (G4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no sterilization) (G5)
Number of subjects: 60
Study: 17238884

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block (Group B) with 1 ml 0.25% bupivacaine and 2 ml i.v. saline as control
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block (Group B)
Number of subjects: 82
Study: 15960852

Group type: EXPERIMENTAL
Intervention: Self-testing of blood glucose group; interpreted with nurse-practitioner to inform adjustment of medication
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose group with personal use of results
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group with three monthly HbA1c measurements; interpreted with nurse-practitioner
Number of subjects: 450
Study: 12324991

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 3577

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 3577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study: 9818639

Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Low potency neuroleptics
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Moderate potency neuroleptics
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Moderate-high potency neuroleptics
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: High potency neuroleptics
Number of subjects: 499
Study: 8631403

Group type: EXPERIMENTAL
Intervention: Early discharge with the axillary drain in situ (n = 39)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those not opting for early discharge)
Number of subjects: 101
Study: 2560283

Group type: EXPERIMENTAL
Intervention: Enalapril for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (as a reference)
Number of subjects: 0
Study: 858019

Group type: EXPERIMENTAL
Intervention: Xeroradiography
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 40
Study: 30516096

Group type: EXPERIMENTAL
Intervention: Two consultations with a spiritual counselor
Number of subjects: 153

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Meaning/Peace experience
Number of subjects: 153
Study: 28234565

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 10
Study: 26436470

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPP-4 inhibitors (general)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23599357

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with olive oil
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 4449

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 4449
Study: 22115228

Group type: EXPERIMENTAL
Intervention: LeGoo (LG)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional vessel loops (VL)
Number of subjects: 110
Study: 19451668

Group type: EXPERIMENTAL
Intervention: Soft-sand walking (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Firm-surface walking (n = 19)
Number of subjects: 38
Study: 15960695

Group type: EXPERIMENTAL
Intervention: Basic intervention (e-mail reminders)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Augmented intervention (e-mail reminders + additional resources)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 628
Study: 12196361

Group type: EXPERIMENTAL
Intervention: 8-week VNCOP-B plus G-CSF regimen
Number of subjects: 306

Group type: COMPARATOR
Intervention: 12-week VNCOP-B plus G-CSF regimen
Number of subjects: 306
Study: 9465841

Group type: EXPERIMENTAL
Intervention: Sirolimus and cyclosporine administered concomitantly (schedule I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sirolimus administered 4 hours after cyclosporine (schedule II)
Number of subjects: 24
Study: 7617182

Group type: EXPERIMENTAL
Intervention: 8 million international units (MIU) of interferon beta-1b (IFNB)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 1.6 million international units (MIU) of interferon beta-1b (IFNB)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 2649124

Group type: EXPERIMENTAL
Intervention: Metoprolol 0.07 mg kg‐1 i.v. (9 patients)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Captopril 1 mg kg‐1 by mouth (11 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Captopril (11 patients)
Number of subjects: 29
Study: 406628

Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28880419

Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study: 26927900

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside infusion
Number of subjects: 350

Group type: COMPARATOR
Intervention: Oral iron sulfate
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside infusion
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside bolus injection
Number of subjects: 350
Study: 24117857

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention by practice nurses
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no motivational interviewing)
Number of subjects: 330
Study: 21947813

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (4, 8, or 12 kcal/kg/week) for 6 months
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (all exercise groups combined)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Exercisers with normal endothelial function (FMD ≥ 5.5%)
Number of subjects: 155
Study: 20696980

Group type: EXPERIMENTAL
Intervention: Adherent group (those who stayed on treatment)
Number of subjects: 3433

Group type: COMPARATOR
Intervention: Nonadherent group (those who discontinued treatment)
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: Adherent group (after recalibration)
Number of subjects: 3433

Group type: EXPERIMENTAL
Intervention: Overall assessment of blood pressure monitoring
Number of subjects: 3433
Study: 18230195

Group type: EXPERIMENTAL
Intervention: Follitropin alfa pen
Number of subjects: 171

Group type: COMPARATOR
Intervention: Follitropin beta pen
Number of subjects: 171
Study: 15813831

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg twice daily
Number of subjects: 30
Study: 12162112

Group type: EXPERIMENTAL
Intervention: Hand exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 26
Study: 9649990

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30
Study: 7544175

Group type: EXPERIMENTAL
Intervention: 35 g resistant starch (100 g amylomaize starch)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Digestible starch
Number of subjects: 7

Group type: COMPARATOR
Intervention: Resistant starch
Number of subjects: 7
Study: 2671116

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg three times daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 170
Study: 795354

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 0
Study: 30699211

Group type: EXPERIMENTAL
Intervention: Nordic walking training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Free walking training
Number of subjects: 33
Study: 28366450

Group type: EXPERIMENTAL
Intervention: Inexperienced surgeons
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 70
Study: 26429655

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 2 mg/kg/d for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study: 23954071

Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy (bupropion SR + nicotine lozenge, nicotine patch + nicotine lozenge)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Monotherapy (bupropion SR, nicotine patch, nicotine lozenge)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Cessation fatigue
Number of subjects: 1504
Study: 22104033

Group type: EXPERIMENTAL
Intervention: 2% viscous lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19588533

Group type: EXPERIMENTAL
Intervention: 1,210 nm laser exposure at fluences of 70, 80, and 90 J/cm(2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1,210 nm laser exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control sites (not exposed to laser)
Number of subjects: 24
Study: 18164922

Group type: COMPARATOR
Intervention: Chronic Pain Sleep Inventory (CPSI) items measuring trouble falling asleep (CPSI1), awakened by pain during the night (CPSI3), and awakened by pain in the morning (CPSI4) on a 100-mm visual analog scale.
Number of subjects: 2674

Group type: COMPARATOR
Intervention: CPSI items overall quality of sleep (CPSI5) on a 100-mm visual analog scale.
Number of subjects: 2674
Study: 15151958

Group type: EXPERIMENTAL
Intervention: Hemoglobin responders (increase > or =2 g/dl)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patients with meaningful improvement in fatigue (FACT Fatigue change score > or =3 points)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patients whose fatigue improved
Number of subjects: 5
Study: 11590519

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) or efavirenz (EFV)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Two NRTIs and one NNRTI
Number of subjects: 5
Study: 9453529

Group type: EXPERIMENTAL
Intervention: Baseline exercise test 1
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Predetermined submaximal level
Number of subjects: 81
Study: 8288662

Group type: EXPERIMENTAL
Intervention: 30 mg enoxaparin every 12 hours (194 patients)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin once daily (203 patients)
Number of subjects: 610

Group type: COMPARATOR
Intervention: 5000 units unfractionated heparin every 8 hours (207 patients)
Number of subjects: 610
Study: 29366744

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 54
Study: 27434056

Group type: COMPARATOR
Intervention: 125 mg L-homoarginine once daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 24685829

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 808
Study: 22892359

Group type: EXPERIMENTAL
Intervention: Insult/nonsexually coercive fantasy material
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: No insult/sexually coercive fantasy material
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Insult/sexually coercive fantasy material
Number of subjects: 59
Study: 20826244

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, followed by 75 mg daily) in addition to aspirin
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo in addition to aspirin
Number of subjects: 750
Study: 18028997

Group type: EXPERIMENTAL
Intervention: Intranasal CO2 treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (air) treatment
Number of subjects: 89
Study: 16861083

Group type: EXPERIMENTAL
Intervention: 95% ethyl alcohol rinse
Number of subjects: 40

Group type: COMPARATOR
Intervention: NaOCl rinse
Number of subjects: 40
Study: 12590230

Group type: EXPERIMENTAL
Intervention: Witzel balloon dilatation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Botulinum toxin (80 units into the LES)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Crossover to Witzel dilatation
Number of subjects: 34